ThyGenX and ThyraMIR

The ThyGenX and ThyraMIR markers can be used to help determine if indeterminate nodules are likely to be malignant

ThyGenX® and ThyraMIR™ are a Panel of molecular markers which improves preoperative diagnostic accuracy for patients with indeterminate thyroid nodules. In addition, the panel can aid in the characterization of malignancy. The panel consists of analytically validated molecular markers and utilizes fine needle aspirate (FNA) specimens. The Thyroid panel is a molecular diagnostic tool utilizing DNA and RNA based markers (BRAF, RAS, RET/PTC and PAX-8-PPARy). Multiple peer-reviewed scientific studies have shown that the mutations and genetic rearrangements, assayed by the panel, correlate with malignant thyroid nodules. Therefore, the panel can aid physicians in diagnosis and patient management decisions.

References

  1. Labourier E, Beaudenon A, Wylie D, Giordano TJ. Multi-categorical testing for miRNA, mRNA and DNA on fine needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology. ENDO 2015. Presented at the 97th Meeting and Expo of the Endocrine Society March 5-8, 2015. SAT-344.

  2. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer statistics review 1975-2011. Section 26. thyroid. http://seer.cancer.gov/csr/1975_2011/

    1. results_merged/sect_26_thyroid.pdf. Accessed October 1, 2015.

  3. Beaudenon-Huibregtse S, Alexander EK, Guttler RB, et al. Centralized molecular testing for oncogenic gene mutations complements the local cytopathological diagnosis of thyroid nodules. Thyroid. 2014;24(10):1479-1487.

  4. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011;96(7): 2016-2206.

  5. Data on File Packet 0001. Interpace Diagnostics. Parsippany, NJ.

  6. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.

  7. Nikiforov YE, Nikiforova MN. Molecular genetics and the diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569-580.

  8. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Thyroid carcinoma Version 2.2014. Available at: www.nccn.org. Accessed October 1, 2015.

  9. Wang CC, Friedman L, Kennedy GC, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 2011;21(3):243-251.